On February 16, 2024, the FDA approved Iovance’s AMTAGVI, the first approved cellular therapy for the treatment of adult patients with unresectable or metastatic melanoma. AMTAGVI is indicated to treat adult patients with unresectable or metastatic melanoma that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF
More Posts
PTAB Issues Final Written Decisions Finding Claims of Aflibercept-related Patents Invalid
Recent Biosimilar Approvals
Biogen Announces FDA Approval of TOFIDENCE, a Tocilizumab Biosimilar Referencing ACTEMRA
PTAB Issues Final Written Decisions Finding Claims of Tocilizumab-related Patents Invalid
Aflibercept IPR Updates
Samsung Bioepis Files Four IPR Petitions on Alexion Eculizumab Patents and One IPR Petition on a Janssen Ustekinumab Patent
Accord BioPharma Announces the Acceptance of BLA for HLX02 (a proposed trastuzumab biosimilar) by FDA
Biogen Launches BYOOVIZ (ranibizumab) in Canada
European Biosimilar Regulatory Updates
Subscribe: Subscribe via RSS
Blogs
Firm/Org